Table 1.
Patient characteristics, HER2/neu amplification and PIK3CA mutations in primary USC cell lines
| CELL LINES ID |
AGE | RACE | STAGE | PIK3CA MUTATIONS |
HER2/neu FISH |
HER2 IHC |
PTEN MUTATIONS |
KRAS MUTATIONS |
RAF MUTATIONS |
AKT MUTATIONS |
|---|---|---|---|---|---|---|---|---|---|---|
| USPC-ARK-1 | 62 | B | IV | 542/1068 | A | 3+ | ND | ND | ND | ND |
| USPC-ARK-2 | 63 | B | IV | ND | A | 3+ | ND | ND | ND | ND |
| USPC-ARK-4 | 73 | W | IV | ND | NA | 0 | ND | ND | ND | ND |
| USPC-ARK-6 | 62 | W | IB | ND | NA | 1+ | ND | ND | ND | ND |
| USPC-ARK-7 | 75 | W | IIC | ND | NA | 2+ | ND | ND | ND | ND |
| USPC-ARK-8 | 88 | W | IIIA | ND | NA | 1+ | ND | ND | ND | ND |
| USPC-ARK-19 | 65 | W | IA | ND | NA | 1+ | ND | ND | ND | ND |
| USPC-ARK-20 | 42 | W | II | 1047/1068 | A | 3+ | ND | ND | ND | ND |
| USPC-ARK-21 | 70 | W | IA | ND | A | 3+ | ND | ND | ND | ND |
FIGO, International Federation of Gynecology and Obstetrics stage 1988; B= black; W= white;
ND= not detected; A= amplified; NA= not amplified.
For comprehensive whole exome genomic results of these cell lines see reference #18